Drugs / [18F] PBR111
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04263337 | Mar 2020 → Aug 2028 expected | brain injury | University of North Carolina, Chapel Hill | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01209156 | Mar 2010 → Jun 2013 | Alzheimer disease | Institute for Neurodegenerative Disorders | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06398392 | Jun → Jul 2024 | — | Prof. Daniele Zullino | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-PBR-111 | “18F-PBR-111 Following Intravenous Administration” NCT01209156 ↗ |
| Known as | PBR-111 | “PBR-111 PET imaging day” NCT01209156 ↗ |
| Modality | Diagnostic / imaging agent | “PBR-111 positron emission tomography (PET) imaging” NCT01209156 ↗ |
| Route | Intravenous | “all subjects will receive a single IV injection of PBR-111” NCT01209156 ↗ |
| Target | TSPO | “[18F]PBR111 is a second-generation TSPO PET radioligand with high signal specificity but a sensitivity to TSPO polymorphism, in comparison with first-generation ligands.” NCT06398392 ↗ |